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Background

Coronavirus disease 2019 (COVID-19) is a syndrome that has been associated with multiple cardiac complications
including myopericarditis. The pathophysiology and treatment for myopericarditis in the setting of COVID-19 infection is still under investigation.

...................................................................................................................................................................................................
Case summary We present a case of a 60-year-old male admitted for dyspnoea due to COVID-19. He developed new ST-

segment elevation, elevated cardiac enzymes, severe left ventricular dysfunction, and high inflammatory markers in
the setting of haemodynamic and respiratory collapse from the viral illness. He was diagnosed with COVID-19induced myopericarditis. He showed rapid clinical improvement with a rapid wean off pressure support, resolution
of electrocardiogram (ECG) findings, and recovery of left ventricular systolic function following treatment with
intravenous immunoglobulin (IVIG) and methylprednisolone.

...................................................................................................................................................................................................
Discussion
COVID-19’s complex and devastating complications continue to create new challenges for clinicians. Cardiac com-

plications, specifically, have been shown to be a signal for worse prognosis in these patients. IVIG and steroids can
inhibit the inflammatory cascade and decrease myocardial injury, with implications in treatment of severe
myopericarditis.
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Learning points
• COVID-19-associated myocarditis can be an indirect complication secondary to an inflammatory cascade.
• Recognition of the potential role of immunomodulation in rapid improvement of cardiac function and stabilization of haemodynamics in
COVID-19 myocardial injury.
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Introduction
COVID-19 infection caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) is known to incite an inflammatory response impacting multiple organ systems, including cardiac injury,
which manifests as elevated cardiac biomarkers with electrodardiographic (ECG) or echocardiographic abnormalities.1
Myopericarditis is the clinical and pathological definition for concurrent pericardial and myocardial inflammation, mainly from cardiotropic viruses. Myocardial involvement can be varied, from focal to
diffuse involvement of one or all four chambers, depending on the severity of illness.2

Timeline

Figure 1 Chest radiograph with bilateral pulmonary infiltrates.

Timeline

Description

.................................................................................................

Table 1

Lab values on admission

Day 0

Patient admitted with acute hypoxic respiratory

Day 0: 4 h

failure due to COVID-19.
Patient intubated for worsening respiratory fail-

after

ure. ECG showed diffuse ST elevation, with

White blood cell count (103)

3.8–10.5

17.9

admission

evidence of acute inflammation and cardiac
injury.

Absolute neutrophil count (103)
Absolute lymphocyte count (103)

1.8–7.4
1.0–3.3

16.5
1.1

Day 1

Lab (units)

Reference Absolute
range
value

.................................................................................................

Patient was started on IVIG and high-dose steroid therapy. TTE showed severe segmental
LV dysfunction.

Haemoglobin (g/dL)

11.5–15.5

14.6

Mean corpuscular volume (fL)
Platelet count (103/lL)

80.0–100.0
150–400

88.7
282

Day 2

Patient was weaned off pressor support with

Sodium (mmol/L)

135–145

138

Day 2–5

resolving shock.
Laboratory values show improvement in inflam-

Potassium (mmol/L)
Chloride (mmol/L)

3.5–5.3
98–107

6
100

Carbon dioxide – serum (mmol/L)

22–31

25

Blood urea nitrogen (mg/dL)
Creatinine (mg/dL)

7–23
0.5–1.3

17
0.96

matory markers and cardiac biomarkers, and
Day 6

recovering organ dysfunction.
Repeat TTE shows recovery of LV systolic
function.

70–99

277

Day 13

Repeat ECG demonstrates resolution of ST
segment abnormalities.

Glucose – serum (mg/dL)
Calcium (mg/dL)
Protein total – serum (g/dL)

8.4–10.5
6.0–8.3

9.3
7.8

Day 17

Patient extubated to non-invasive ventilation

Albumin (g/dL)

3.3–5.0

3.4

Day 20

support.
Patient was reintubated and required tracheos-

Total bilirubin (mg/dL)
Alkaline phosphatase (l/L)

0.2–1.2
40–120

0.7
137

4–32

134

4–33
7.32–7.43

137
7.09

tomy for persistent respiratory failure due to

Aspartate aminotransferase (l/L)

Day 35

aspiration.
Full TTE confirms continued LV recovery.

Alanine aminotransferase (l/L)
pH – arterial

Day 38

Tracheostomy was successfully decannulated.

Lactate (arterial) (mmol/L)

0.5–2.0

1.4

Day 52

Patient was discharged from hospital to physical
rehabilitation.

pCO2 (mmHg)
C-reactive protein (mg/dL)

41–51
<0.40

101
29.35

Ferritin (ng/mL)
Lactate dehydrogenase (U/L)
Procalcitonin (ng/mL)

Case presentation
A 60-year-old male with past medical history of hypertension
and hyperlipidaemia presented to the emergency department
with 8 days of fevers, cough, and worsening dyspnoea, with
mild abdominal pain and diarrhoea despite completing a 3-day
course of azithromycin as an outpatient. He denied chest pain,

D-dimer (ng/mL)
High-sensitivity troponin (ng/L)
Creatine kinase, serum (U/L)

a

15–150

6379

135–225
0.02–0.10

588
0.36

<230

458

<6 – 14
30–200

582
279

Creatine kinase-MB (ng/mL)

0–6.7

28.2

Serum pro-brain natriuretic peptide (pg/mL)a

0–300

15642

Measured on hospital day 3.
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Figure 2 (A) ECG on day 1 shows diffuse ST elevation and PR depression in precordial and limb leads, reciprocal ST depression, and PR elevation
in aVR. (B) Day 6 shows incomplete right bundle branch block and horizontal ST depression in precordial and limb leads. (C) Day 13 shows sinus
tachycardia without ST or T wave abnormalities.

nausea, or vomiting. The patient was afebrile with maximum
temperature of 37.4 C, heart rate at 96 b.p.m., and peripheral
oxygen saturation (SpO2) of 87%. The physical exam demonstrated clear lungs and tachypnoea.
The nasopharyngeal swab was positive for SARS-CoV-2 by reverse
transcription–polymerase chain reaction (RT–PCR), and the chest
radiograph showed severe bilateral opacities (Figure 1). Admission
labs were significant for lymphocytopenia, elevated inflammatory
markers, and liver dysfunction. Initial high-sensitivity troponin, creatine kinase, and creatine kinase-MB (CK-MB) were also elevated
(Table 1).
The patient was initially placed on a non-rebreather mask with
supplemental oxygen via nasal cannula and placed in the prone position, but SpO2 remained at 82%. He was quickly intubated for acute
hypoxaemic respiratory failure and started on hydroxychloroquine
therapy for severe COVID-19 infection.

..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.

ECG obtained after admission demonstrated diffuse new STsegment elevation, with QTc interval measured at 437 ms (Figure 2A).
Transthoracic echocardiogram (TTE) was significant for severe segmental left ventricular (LV) systolic dysfunction, ejection fraction (EF)
15–20% with hypokinesis of the apex, distal anterior septum, and anterior and lateral walls, with a small pericardial effusion. Right ventricular size and function were normal (Figure 3; Supplementary
material online, Videos 1 and 2).
Based on diffuse ECG changes suggestive of pericarditis, TTE findings, and laboratory evidence of systemic inflammation, the patient
was initiated on treatment of fulminant myopericarditis on hospital
day 1 with a 4-day regimen of intravenous immunoglobulin (IVIG) 20
g daily and methylprednisolone (50 mg every 6 h).
After the patient was intubated, haemodynamic support
with epinephrine was initially started and weaned off 1 day after
initiation of high-dose steroids and IVIG. Over the next few days,
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Figure 3 (A) TTE in parasternal long-axis view at end systole,
demonstrating severe LV systolic dysfunction. (B) Subcostal view
with small pericardial effusion. (C) Repeat echocardiogram on day 6
in three-chamber view at end systole, demonstrating normal LV
function. (D) Resolution of pericardial effusion on hospital day 6. (E)
TTE at day 35, showing continued normal systolic function in the
parasternal long-axis view at end systole. (F) No further pericardial
effusion on subcostal view.

he remained afebrile with improving haemodynamics. Laboratory
values demonstrated recovery of organ perfusion and inflammation (Figure 4).
Follow-up limited TTE on hospital day 6 demonstrated recovery
of LV systolic function, confirmed again with full TTE on day 35.
Previous areas of regional hypokinesis were no longer appreciated
(Figure 3; Supplementary material online, Videos 3 and 4). A repeat
ECG on day 6 was noted with transient horizontal ST depressions
across precordial and limb leads (Figure 2B), before resolution of all
ST–T wave abnormalities on follow-up ECG on day 13 (Figure 2C).
He remained off pressor support and was extubated on hospital day
17; however, he required reintubation within 3 days for persistent respiratory failure due to aspiration. A tracheostomy was performed
which was successfully decannulated on hospital day 38. The patient
was ultimately discharged for physical rehabilitation on hospital
day 52.

Discussion
COVID-19 is known to cause elevated cardiac biomarkers, and levels
are overall higher in more severe cases of patients infected with
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SARS-CoV2. Cardiac injury, in turn, is associated with increased mortality.1 ECG changes with a positive troponin that normally would
proceed to coronary angiography are now evaluated on a case by
case basis, as ST-segment elevation in patients with COVID-19 has a
high association with non-obstructive coronary disease. Some of
these cases were subsequently diagnosed and managed as
myocarditis.3
Our patient’s presentation was most consistent with COVID-19
myocarditis, with concurrent pericarditis diagnosed via diffuse STsegment elevation on ECG and pericardial effusion. The diagnosis of
stress cardiomyopathy and septic cardiomyopathy was entertained;
however, our patient did not have the classic regional wall motion
abnormalities4 or LV dilation5 typically seen in those cases of cardiac
dysfunction, respectively.
Although cases of COVID-19 myocarditis and myopericarditis
have been reported in the literature,6–8 the overall prevalence
and pathophysiology of this disease manifestation are not well
understood. Proposed mechanisms for acute myocardial injury
include direct invasion via angiotensin-converting enzyme 2
(ACE2) expressed in the heart, or as a result of an overwhelming cytokine storm.9 The use of immunosuppressive therapies
such as IVIG and steroids for other forms of myocarditis has
been well studied, with a reported decrease in inflammatory
markers and improvement in LVEF.10 In the COVID-19 literature, a case series successfully used IVIG in patients with rapid
clinical deterioration and elevated inflammatory markers to suppress the inflammatory cascade.11 Another case report documents a patient with myocarditis who was treated with IVIG
and steroids with favourable results.12
Our case uniquely demonstrates rapid reversal of cardiac injury
associated with COVID-19 after the patient was started on immunomodulating treatment, and a correlating trend with decreasing inflammatory markers. Taken together, this supports the hypothesis of
myocardial injury as a result of cytokine storm. Targeted treatment
of inflammation with IVIG and steroids led to simultaneous reduction
in inflammatory markers and cardiac enzyme levels, after which there
was demonstrated improvement in cardiac function both clinically
and by echocardiogram. Targeted anti-inflammatory therapy for
myocardial injury in severe COVID-19 infection may improve the
high mortality rates usually associated with elevated troponin levels
in these patients. Our patient also demonstrated improvement in
non-cardiac COVID-19 symptoms after therapy with IVIG, with
reduced oxygen requirements following 1 day of treatment. This
timeline for clinical improvement is significantly more accelerated
than what is usually observed with hydroxychloroquine and steroid
treatment alone.13,14

Conclusion
The natural history of cardiac injury related to SARS-CoV2 infection
is not well understood, and usual diagnostic tools such as TTE,
advanced imaging, and angiography are often limited in use to decrease the spread of infection exposure. In patients with increasing cardiac biomarkers, evidence of systemic inflammation and
a low suspicion for acute coronary syndrome, inhibiting the

Management of COVID-19 myopericarditis with reversal of cardiac dysfunction after blunting of cytokine storm

Figure 4 Graphs of laboratory values following steroid and IVIG treatment. Decreasing cardiac biomarker trends through Day 5: (A) high-sensitivity troponin; (B) CK-MB. Decreasing inflammatory markers through Day 9: (C) ferritin; (D) C-reactive protein; (E) procalcitonin; (F) D-dimer. Initial
worsening then improvement through Day 9 of (G) hepatic function; (H) renal function.
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inflammatory cascade may also treat the resulting myocarditis
and reverse cardiac injury.
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